The medtech giant was forced to shave $US100 million off its revenue forecasts for capitalising on a competitor’s recall, with the stock falling 5 per cent.
Brisbane Times – Business
The medtech giant was forced to shave $US100 million off its revenue forecasts for capitalising on a competitor’s recall, with the stock falling 5 per cent.
Brisbane Times – Business